Argenx
Argenx is a biopharmaceutical company based in the Netherlands, dedicated to developing antibody-based therapies for rare autoimmune diseases.
Top Stages
4 past transactions
OncoVerity
Series A in 2024
OncoVerity specializes in advancing targeted therapies for cancer. It focuses on optimizing the development of cusatuzumab, a novel anti-CD70 antibody.
Food and Drug Administration - Priority Review Voucher
Acquisition in 2022
Priority Review voucher is an e-marketing application for efgartigimod.
OncoVerity
Venture Round in 2022
OncoVerity specializes in advancing targeted therapies for cancer. It focuses on optimizing the development of cusatuzumab, a novel anti-CD70 antibody.
Halozyme Therapeutics
Post in 2019
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel drug delivery technologies. Its core product, Enhanze™, enables subcutaneous delivery of injectable biologics, enhancing absorption and dispersion. The company's pipeline includes products targeting various therapeutic areas, with key partnerships to apply its technology to therapeutic biologics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.